Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04750278 · ClinicalTrials.gov registry record · Phase 2
A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19
A Phase 2 study, sponsored by Foresee Pharmaceuticals Co..
- Terminated
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT04750278: Clinical Trial Phase 2 study, sponsored by Foresee Pharmaceuticals Co..
NCT04750278 is a Phase 2 study that was terminated before completion, run by Foresee Pharmaceuticals Co.. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04750278, a Phase 2 study, was terminated before completion, sponsored by Foresee Pharmaceuticals Co..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a Phase 2/3, randomized, double blind, placebo controlled, multicenter study to evaluate the efficacy and safety of FP-025 in adult patients with severe to critical COVID 19 with associated ARDS.
Primary Outcome
Percentage of patients alive and not requiring non-invasive or invasive ventilation at Day 28
Interventions
- DRUG Placebo
- DRUG FP-025 100 mg
- DRUG FP-025 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2021-04-06 |
| Est. Completion | 2022-04-18 |
| Phase | Phase 2 |
Why NCT04750278 stopped before completion
NCT04750278 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04750278 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04750278 about?
NCT04750278 is a clinical study titled "A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19". This is a Phase 2/3, randomized, double blind, placebo controlled, multicenter study to evaluate the efficacy and safety of FP-025 in adult patients with severe to critical COVID 19 with associated ARDS.
What is the current status of trial NCT04750278?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2021-04-06. Estimated completion is 2022-04-18.
What interventions are being tested in trial NCT04750278?
The interventions under investigation include: Placebo (DRUG), FP-025 100 mg (DRUG), FP-025 300 mg (DRUG).
Who is sponsoring clinical trial NCT04750278?
This trial is sponsored by Foresee Pharmaceuticals Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04750278's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI